After putting in some more thought and research I have come to the conclusion that priority review at this point of time is the more likely scenario.It appears for mine that the criteria for such a outcome safety and efficacy have absolutely been met.The biologics or surrogate end points if you like have only just been announced,and also appear for mine to meet the accelerated approval criteria,but the timeline appears too soon for this designation at this time .However I note that once priority review is obtained , the company can then apply for accelerated approval and will receive an answer in 6 months opposed to the standard 10 months ,for accelerated approval deliberation.
These are purely my musings and understandings and should not be used as financial advice or guidance
Media, page-557
-
- There are more pages in this discussion • 187 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.005(1.19%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.0¢ | 41.5¢ | $65.09K | 156.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 110983 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 77344 | 9 |
View Market Depth
| Last trade - 10.24am 25/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |